Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma.

abstract：BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...

journal_title：Thoracic cancer

authors： Zhao YL,Li JB,Li YJ,Li SJ,Zhou SH,Xia H

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

journal_title：Thoracic cancer

authors： Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

journal_title：Thoracic cancer

authors： Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...

journal_title：Thoracic cancer

authors： Zhuo M,Zheng Q,Chi Y,Jia B,Zhao J,Wu M,An T,Wang Y,Li J,Zhao X,Yang X,Zhong J,Chen H,Dong Z,Wang J,Zhai X,Wang Z

更新日期：2019-05-01 00:00:00

abstract：:Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

journal_title：Thoracic cancer

authors： Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

更新日期：2021-01-12 00:00:00

abstract：BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

journal_title：Thoracic cancer

authors： Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

更新日期：2020-04-01 00:00:00

abstract：:The main recurrence pattern for lung cancer patients after radical surgery is distant metastasis. The probability of pancreatic metastasis in patients diagnosed with lung squamous cell carcinoma is 0.02%, with a poor prognosis. Chemotherapy is the preferred treatment for recurrence. Single lesions or oligometastasis c...

journal_title：Thoracic cancer

authors： Wang W,Huang C,Wu S,Liu Z,Liu L,Li L,Li S

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical rec...

journal_title：Thoracic cancer

authors： Sonehara K,Tateishi K,Fukushima T,Komatsu M,Yamamoto H,Koizumi T,Hanaoka M

更新日期：2019-09-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...

journal_title：Thoracic cancer

authors： Guo R,Li Y,Bie Z,Li B,Li X

更新日期：2020-07-01 00:00:00

abstract：:A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

journal_title：Thoracic cancer

authors： Dango S,Guenter J,Passlick B

更新日期：2010-07-01 00:00:00

abstract：BACKGROUND:Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHO...

journal_title：Thoracic cancer

authors： Hayakawa D,Takahashi F,Mitsuishi Y,Tajima K,Hidayat M,Winardi W,Ihara H,Kanamori K,Matsumoto N,Asao T,Ko R,Shukuya T,Takamochi K,Hayashi T,Suehara Y,Takeda Nakamura I,Ueno T,Kohsaka S,Mano H,Takahashi K

更新日期：2020-01-01 00:00:00

abstract：:A 59-year-old man with previous anaplastic large cell T-cell lymphoma stage 3A was admitted with an isolated positron emission tomography(PET)-positive spot in a subcarinal lymph node. Diagnosis was achieved with endobronchial ultrasound-guided fine-needle aspiration demonstrating a well-differentiated squamous cell c...

journal_title：Thoracic cancer

authors： Eckardt J,Olsen KE,Petersen H

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND:We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM). METHODS:Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who re...

journal_title：Thoracic cancer

authors： Zhu Y,Fu L,Jing W,Guo D,Kong L,Yu J

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....

journal_title：Thoracic cancer

authors： Zhang X,Kong M,Zhang Z,Xu S,Yan F,Wei L,Zhou J

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

journal_title：Thoracic cancer

authors： Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of ...

journal_title：Thoracic cancer

authors： Zhang L,Bai L,Liu X,Liu Y,Li S,Liu J,Zhang S,Yang C,Ren X,Cheng Y

更新日期：2020-05-01 00:00:00

abstract：:Selected patients with non small-cell lung cancer (NSCLC) with mediastinal lymph node involvement may have a survival benefit from surgical resection, particularly if mediastinal nodal down-staging occurs after induction therapy and complete resection is achieved with lobectomy. Accurate re-staging of the mediastinum ...

journal_title：Thoracic cancer

authors： Khoo KL

更新日期：2012-05-01 00:00:00

abstract：:Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

journal_title：Thoracic cancer

authors： Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

更新日期：2020-09-01 00:00:00

abstract：:We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...

journal_title：Thoracic cancer

authors： Matsukuma S,Obara K,Kono T,Takeo H,Sato K

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Growing evidence indicates that high phosphoserine phosphatase (PSPH) expression is associated with tumor prognosis in many types of cancers. However, the role of PSPH in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to investigate the clinical significance of PSPH in NSCLC. M...

journal_title：Thoracic cancer

authors： Liao L,Yu H,Ge M,Zhan Q,Huang R,Ji X,Liang X,Zhou X

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...

journal_title：Thoracic cancer

authors： Hsia TC,Liang JA,Li CC,Chien CR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...

journal_title：Thoracic cancer

authors： Ke C,Zhu K,Sun Y,Ni Y,Zhang Z,Li X

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

journal_title：Thoracic cancer

authors： Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

journal_title：Thoracic cancer

authors： Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:Computed tomography (CT)-guided percutaneous implantation of 125 Iodine radioactive seeds requires the precise arrangement of seeds by tumor shape. We tested whether selecting target areas, including subclinical areas around tumors, can influence locoregional recurrence in patients with non-small cell lung c...

journal_title：Thoracic cancer

authors： Yan WL,Lv JS,Guan ZY,Wang LY,Yang JK,Liang JX

更新日期：2017-05-01 00:00:00

abstract：:Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-f...

journal_title：Thoracic cancer

authors： Okuma Y,Morikawa K,Tanaka H,Yokoyama T,Itani H,Horiuchi K,Nakagawa H,Takahashi N,Bessho A,Soejima K,Kishi K,Togashi A,Kanai Y,Ueda K,Horimoto K,Matsutani N,Seki N

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

journal_title：Thoracic cancer

authors： Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

更新日期：2019-04-01 00:00:00

abstract：:Immunoglobulin light-chain (AL) amyloidosis is a monoclonal plasma cell neoplasm that has a tendency to bleed easily. However, the potential risks of transbronchial biopsy in such cases have not been fully proven. Here, we report a case of parotid and intrathoracic AL amyloid tumors that presented as endobronchial pro...

journal_title：Thoracic cancer

authors： Tomono H,Soda H,Fukuda Y,Tanaka Y,Ono S,Shimada M,Iwasaki K,Hisanaga M,Yamaguchi H,Mukae H

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

journal_title：Thoracic cancer

authors： Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

更新日期：2020-02-01 00:00:00